News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: exwannabe post# 243173

Wednesday, 11/18/2015 10:11:31 PM

Wednesday, November 18, 2015 10:11:31 PM

Post# of 347009

Nothing at all negative in what I am saying here, Just correcting sunstar's math. In the long run the total events will certainly be 1:1.



ex, you are not going to give no chance for complete responses ? More patients in the Bavi arm will certainly have better ECOG status and that factor.... just may be enough to allow for some complete responses.

Time will tell.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y